Drugs / Expanded autologous bone marrow-derived mesenchymal stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03343782 | Nov 2017 → Aug 2019 | type 2 diabetes mellitus | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded autologous bone marrow-derived mesenchymal stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03343782 ↗ |
| Known as | BM-MSCs | “Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (T2DM)” PMID 34080789 ↗ Jun 2021 |
| Modality | Cell therapy | “Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy” PMID 34080789 ↗ Jun 2021 |
| Route | Intravenous | “T2DM patients were enrolled, randomly assigned (1:1) by a computer-based system into the intravenous and dorsal pancreatic arterial groups” PMID 34080789 ↗ Jun 2021 |